Inovio Pharmaceuticals Inc  

(Public, NASDAQ:INO)   Watch this stock  
Find more results for AMEX:INO
7.99
-0.51 (-6.00%)
Jun 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.99 - 8.36
52 week 6.33 - 14.20
Open 8.29
Vol / Avg. 1.67M/1.24M
Mkt cap 610.38M
P/E     -
Div/yield     -
EPS -0.59
Shares 71.81M
Beta 2.88
Inst. own 26%
Aug 10, 2015
Q2 2015 Inovio Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 4, 2015
Inovio Pharmaceuticals Inc at Jefferies Global Healthcare Conference
May 11, 2015
Q1 2015 Inovio Pharmaceuticals Inc Earnings Release
May 11, 2015
Q1 2015 Inovio Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -204.83% -345.61%
Operating margin -161.95% -377.71%
EBITD margin - -362.17%
Return on average assets -34.01% -32.84%
Return on average equity -39.60% -44.14%
Employees 106 -
CDP Score - -

Address

10480 Wateridge Cir
SAN DIEGO, CA 92121-5773
United States - Map
+1-858-5976006 (Phone)
+1-858-4041392 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Inovio Pharmaceuticals, Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola. With its immunotherapy platform consisting of SynCon products, as well as its CELLECTRA electroporation delivery technology, Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovio's immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.

Officers and directors

J. Joseph Kim Ph.D. President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Peter D. Kies Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Niranjan Y. Sardesai Ph.D. Chief Operating Officer
Age: 47
Bio & Compensation  - Reuters
Mark L. Bagarazzi M.D. Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Avtar S. Dhillon M.D. Non-Executive Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Nancy J. Wysenski Director
Age: 57
Bio & Compensation  - Reuters
Simon X. Benito Independent Director
Age: 70
Bio & Compensation  - Reuters
Angel Cabrera Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Morton Collins Ph.D. Independent Director
Age: 79
Bio & Compensation  - Reuters